VeracyteVCYT -4.63%75 14-Day RSI is 64.31 as of Jul. 04, 2026. GuruFocus rates VCYT with a GF Score™ of 75/100 and a GF Value™ of $38.19 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Veracyte ranks worse than 81.65% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-04), Veracyte's 14-Day RSI is 64.31.
The industry rank for Veracyte's 14-Day RSI or its related term are showing as below:
VCYT's 14-Day RSI is ranked worse than 81.65% of 218
companies
in the Medical Diagnostics & Research industry
Industry Median: 49.435
vs VCYT: 64.31
Veracyte (NAS:VCYT) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Veracyte 14-Day RSI Related Terms
VCYT vs RDNT, SHC, BLLN: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, Veracyte's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Veracyte's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (VCYT) has a 14-Day RSI of 64.31 as of Jul. 04, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Veracyte and its competitors. According to the industry distribution chart, Veracyte ranks #178 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 81.7%.
Is Veracyte's 14-Day RSI too high?
Veracyte's current 14-Day RSI is 64.31. The Medical Diagnostics & Research industry median 14-Day RSI is 49.44. Veracyte's value of 64.31 is 30.1% above this industry median. Based on the distribution chart, Veracyte ranks #178 out of 218 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Veracyte has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's 14-Day RSI compare to RDNT and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Veracyte ranks #178 out of 218 companies for 14-Day RSI. This places Veracyte in the lower half of its industry. The industry median 14-Day RSI is 49.44. Veracyte's value of 64.31 is 30.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 49.44, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veracyte's current 14-Day RSI of 64.31 is 30.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Veracyte and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 49.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veracyte's current 14-Day RSI is 64.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Significantly Overvalued. The stock's GF Value™ is $38.19, compared to a current price of $57.10 — trading 49.5% above its estimated fair value. The current 14-Day RSI is 64.31 and 30.1% above the Medical Diagnostics & Research industry median of 49.44. Veracyte's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Veracyte (VCYT), the current 14-Day RSI is 64.31 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veracyte (VCYT) Overvalued in 2026?
Based on GuruFocus' analysis, Veracyte stock appears to be overvalued.
The current stock price of $57.10 is trading 49.5% above its estimated GF Value™ of $38.19.
GuruFocus considers Veracyte to be Significantly Overvalued.
Key valuation signals for VCYT:
14-Day RSI: 64.31
GF Value™: $38.19 vs. price of $57.10 (49.5% above fair value)
Industry Position: 30.1% above the Medical Diagnostics & Research median (#178 of 218)
No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score
Get the complete analysis for VCYT
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCYT has been successfully added to your 